Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06523218

A Clinical Trial to Investigate the Efficacy of a Supplement to Improve and Maintain Cognitive Function and Memory

This study will evaluate the efficacy of 1MD Nutrition's MindMD supplement in improving and maintaining cognitive function and memory. The randomized controlled trial will include 50 healthy participants aged 50-75 years, lasting for 3 months. Participants will be randomized to receive either the test product or a placebo.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Cognitive Decline Cognition Disorders Cognitive Dysfunction Cognitive Function Mental Disorders Neurocognitive Disorders

Age range

50 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Santa Monica, California, 90404, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 50-75 years
  • Regular experience of symptoms related to cognitive decline (e.g., forgetfulness, lack of focus, brain fog)
  • Generally healthy without uncontrolled chronic diseases
  • Willingness to avoid certain medications and supplements during the study

Exclusion criteria

  • Any medical condition or treatment impacting cognitive ability Mental health or neurological disorders
  • Severe allergies, particularly to soy or other product ingredients
  • Taking blood thinning medication
  • Recent or planned surgeries
  • Major illness in the past three months

Treatment and study plan

MindMD Supplement

Dietary Supplement

Participants will take two capsules of the MindMD supplement once daily with their morning meal for a duration of 3 months. The supplement is designed to improve and maintain cognitive function and memory.

Placebo

Other

Participants will take two capsules of the placebo once daily with their morning meal for a duration of 3 months. The placebo is designed to be indistinguishable in appearance and administration from the MindMD supplement to ensure blinding.

Primary outcomes

  1. Cognitive Function and Memory Improvement

    Time frame: Baseline, Month 2, and Month 3

    Measurement of cognitive function and memory through Cognitive Battery Testing. The Cognitive Battery Testing includes assessments such as Polygons, Double Trouble, Feature Match, Paired Associates, Digit Span, and Spatial Planning. These assessments provide objective measurements of various cognitive functions, including processing speed, memory recall, selective attention, and executive function.

Secondary outcomes

  1. Participants' Perceptions of Cognitive Function and Memory using the Cognitive Function Questionnaire

    Time frame: Baseline, Month 1, Month 2, and Month 3

    Evaluation of participants' self-reported perceptions of the effect of the MindMD supplement on cognitive function and memory. This includes aspects such as focus and attentiveness, comprehension and mental clarity, learning acuity, absentmindedness, and overall quality of life. These perceptions will be measured through the Cognitive Function Questionnaire (CFQ) at specified time points: Baseline (Day 0), Month 1, Month 2, and Month 3.

  2. Participants' Quality of Life

    Time frame: Baseline, Month 1, Month 2, and Month 3

    Assessment of participants' quality of life using the WHO-5 Well-Being Index. These assessments will be conducted at Baseline (Day 0), Month 1, Month 2, and Month 3.

  3. Participants' Focus and Attentiveness

    Time frame: Baseline, Month 1, Month 2, and Month 3

    Evaluation of participants' focus and attentiveness using the Visual Analog Scale (VAS). These assessments will be conducted at Baseline (Day 0), Month 1, Month 2, and Month 3.

Sponsors and collaborators

Lead sponsor

Scale Media Inc

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jul 26, 2024
Registry last updated
Jul 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.